Trending...
- Financial Solutions Inc. Receives the 2020 Best of Sheridan Wyoming Award
- Wellesley Dermatologists, Premier Dermatology, Offer Helpful Information about Hair Restoration
- The Business Consultant behind The First Black-owned BP
CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's common stock on November 30, 2020, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $3.31 per share, which is equal to the closing price of Akebia's common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of the company's Inducement Award Program and a stock option agreement covering the grant.
More on Boston Chron
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Kristen K. Sheppard, Esq.
[email protected]
SOURCE Akebia Therapeutics
Related Links
http://www.akebia.com
The options have an exercise price of $3.31 per share, which is equal to the closing price of Akebia's common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of the company's Inducement Award Program and a stock option agreement covering the grant.
More on Boston Chron
- Boston: 2021 day of celebration to honor Rev. Dr. Martin Luther King Jr.
- City houses 1,700 children experiencing housing instability through Boston housing authority vouchers
- Thirteen MBK Senior Living Communities Receive "2021 Best of Senior Living" Distinction
- Grassroots Advocacy Group Urges Biden Administration to Appoint a Doctoral Level Mental Health Professional to Lead SAMHSA
- Boston: January 2021: Latest updates from the Department of Neighborhood Development
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Kristen K. Sheppard, Esq.
[email protected]
SOURCE Akebia Therapeutics
Related Links
http://www.akebia.com
Filed Under: Business
0 Comments
Latest on Boston Chron
- Boston: Mayor Walsh announces 2021 day of celebration in honor of Rev. Dr. Martin Luther King Jr.
- Wanderful to Host Final Edition of Moving Forward: An Anti-Racism Town Hall for the Travel Industry
- AUA College of Medicine Establishes Admissions Agreement with Mississippi Valley State University
- Mayor Walsh announces city houses 1,700 children experiencing housing instability through Boston housing authority vouchers
- Dollyhood Records Signs Distribution Deal With Sony!
- Artists selected for public art projects at Boston Arts Academy and East Boston Police Station
- Eaton Vance Tax-Advantaged Dividend Income Fund January 2021 Distribution
- Loomis Sayles Promotes Kyra Fecteau to Portfolio Manager for Securitized Credit Strategies Managed by the Mortgage & Structured Finance Team
- West Coast Recording Artist, Composer and Actor, Blue Ragg$ Releases New Music & Theatrical Video
- Swaggerty's Receives Highest Possible Grade from BRC Food Safety Auditors for 8th Consecutive Year
- Be an Example, Get the Covid Shot
- Former CEO & Founder of Five Star Custom Foods, Acquired by Cargill, Joins CEO Coaching International
- Thiel College names Terry Eddy to Board of Trustees
- Civics Education Drive: Edward M. Kennedy Institute Offers Online Classes to 10,000 Students This Semester
- Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep
- NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021
- Amwell Announces Pricing of Secondary Public Offering
- Atlantic Power Agrees to be Acquired by I Squared Capital
- "Diamond Fuji" to be Seen from TOKYO SKYTREE in February
- BIOMODEX Expands Product Offerings with Innovative Transseptal Puncture Training Solution